Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Eplerenone is a prescription aldosterone antagonist. It improves survival in stable adults with symptomatic heart failure with reduced ejection fraction after acute myocardial infarction and treats hypertension in adults. Tablets come in 25 mg and 50 mg strengths.
read more about eplerenone ...Eplerenone binds mineralocorticoid receptors and blocks aldosterone binding. Aldosterone is part of the renin-angiotensin-aldosterone system and promotes sodium retention and potassium excretion. Blocking its receptor changes sodium and potassium handling and contributes to lower blood pressure and heart failure treatment after myocardial infarction.
Eplerenone is used in stable adults with symptomatic heart failure and left ventricular ejection fraction of 40 percent or less after acute myocardial infarction. It is also approved for adult hypertension. Serum potassium and kidney function are assessed before therapy and during treatment.
Post-myocardial-infarction heart failure starts at 25 mg once daily and is titrated toward 50 mg once daily within four weeks as tolerated. Hypertension starts at 50 mg once daily and can increase to 50 mg twice daily when blood pressure response is inadequate. Potassium levels guide dose changes.
Hyperkalemia is the main serious risk and is more common with reduced kidney function, diabetes, proteinuria, or interacting medicines. Eplerenone is contraindicated when serum potassium exceeds 5.5 mEq per L at initiation, when creatinine clearance is 30 mL per minute or lower, and with strong CYP3A inhibitors.
Eplerenone treats adult hypertension and selected heart failure after acute myocardial infarction.
The labeled starting dose is 25 mg once daily, with titration toward 50 mg once daily.
The recommended hypertension starting dose is 50 mg once daily.
Eplerenone can raise serum potassium, especially in patients with kidney disease or interacting medicines.
Eplerenone. https://www.ncbi.nlm.nih.gov/books/NBK553100/. Date Accessed September 29, 2026.
Eplerenone: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a603004.html. Date Accessed September 29, 2026.
Eplerenone, a Selective Aldosterone Blocker, in Patients With Left Ventricular Dysfunction After Myocardial Infarction. https://pubmed.ncbi.nlm.nih.gov/12668699/. Date Accessed September 29, 2026.
EPLERENONE Tablets Prescribing Information. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0886e4e-5710-4053-9270-4d7de34068e7. Date Accessed September 29, 2026.
INSPRA (Eplerenone) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1a52bedc-8e2c-4116-a296-a87770676b4a. Date Accessed September 29, 2026.